A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?